Efaproxiral is an effective addition to WBRT in patients with brain metastases
Pippa Murdie
This article has no abstract so we have provided the first paragraph of the full text.
Metastasis of cancer to the brain is common, affecting as many as 170,000 individuals annually in the US alone. Whole-brain radiation therapy (WBRT) produces local control/response rates of 50–75%, and other treatments have also shown some success; however, post-diagnosis survival is poor, at a median of approximately 4.5 months. Because tumor resistance to radiation is increased by hypoxia, treatments to reduce hypoxia could be valuable. Efaproxiral changes the conformational structure of hemoglobin, thereby assisting oxygen release and improving tumor oxygenation. In the REACH/RT-009 study, Suh et al. tested whether addition of efaproxiral to WBRT and supplemental oxygen resulted in longer survival than combined WBRT and oxygen.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Regulatory T-cell development: is Foxp3 the decider?Nature Medicine News and Views (01 Mar 2007)